Brodalumab is yet another monoclonal antibody with anti-IL-17A activity approved for the treatment of moderate-severe psoriasis in those who are adequate candidates for phototherapy or systemic therapy and have either lost response or failed to respond to systemic therapy [27]. The gene discussed is IL17A; the disease is psoriasis.